BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease. Inflammopharmacol 2010;18:73-85. [DOI: 10.1007/s10787-010-0032-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhao S, Adebiyi MG, Zhang Y, Couturier JP, Fan X, Zhang H, Kellems RE, Lewis DE, Xia Y. Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease. FASEB J 2018;32:2855-65. [PMID: 29401601 DOI: 10.1096/fj.201600788RR] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
2 Silva I, Pinto R, Mateus V. Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis. J Clin Med 2019;8:E1574. [PMID: 31581545 DOI: 10.3390/jcm8101574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
3 Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702. [PMID: 23954895 DOI: 10.1038/nrd4099] [Cited by in Crossref: 292] [Cited by in F6Publishing: 276] [Article Influence: 32.4] [Reference Citation Analysis]
4 Kim M, Park SW, Kim M, D'Agati VD, Lee HT. Isoflurane activates intestinal sphingosine kinase to protect against renal ischemia-reperfusion-induced liver and intestine injury. Anesthesiology 2011;114:363-73. [PMID: 21245730 DOI: 10.1097/ALN.0b013e3182070c3a] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
5 Orr Gandy KA, Obeid LM. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta 2013;1831:157-66. [PMID: 22801037 DOI: 10.1016/j.bbalip.2012.07.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]
6 Xia P, Wadham C. Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling. Cytokine Growth Factor Rev 2011;22:45-53. [PMID: 21051273 DOI: 10.1016/j.cytogfr.2010.09.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
7 Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther 2020;207:107464. [PMID: 31863815 DOI: 10.1016/j.pharmthera.2019.107464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
8 Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, Upson JJ, Paul E, Donahue H, Mosher TJ, Smith CD. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology 2011;19:75-87. [PMID: 20936538 DOI: 10.1007/s10787-010-0060-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
9 Pulkoski-Gross MJ, Uys JD, Orr-Gandy KA, Coant N, Bialkowska AB, Szulc ZM, Bai A, Bielawska A, Townsend DM, Hannun YA, Obeid LM, Snider AJ. Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat 2017;130:47-56. [PMID: 28377281 DOI: 10.1016/j.prostaglandins.2017.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
10 Abdel Hadi L, Di Vito C, Riboni L. Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces. Mediators Inflamm 2016;2016:3827684. [PMID: 26880864 DOI: 10.1155/2016/3827684] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
11 Abdin AA. Targeting sphingosine kinase 1 (SphK1) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental ulcerative colitis in rats. Eur J Pharmacol. 2013;718:145-153. [PMID: 24055189 DOI: 10.1016/j.ejphar.2013.08.040] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
12 Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, Giussani P. Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases. Front Pharmacol 2019;10:807. [PMID: 31427962 DOI: 10.3389/fphar.2019.00807] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
13 Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 2013;280:5317-36. [PMID: 23638983 DOI: 10.1111/febs.12314] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 12.9] [Reference Citation Analysis]
14 Hatoum D, Haddadi N, Lin Y, Nassif NT, McGowan EM. Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget. Oncotarget 2017;8:36898-929. [PMID: 28415564 DOI: 10.18632/oncotarget.16370] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 13.5] [Reference Citation Analysis]
15 Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther 2015;14:2744-52. [PMID: 26494858 DOI: 10.1158/1535-7163.MCT-15-0279] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
16 Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, Macdonald TL. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 2011;54:3524-48. [PMID: 21495716 DOI: 10.1021/jm2001053] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
17 Shi Y, Qiao J, Mu B, Zuo B, Yuan J. 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway. Biochemical and Biophysical Research Communications 2017;493:286-90. [DOI: 10.1016/j.bbrc.2017.09.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Childress ES, Kharel Y, Brown AM, Bevan DR, Lynch KR, Santos WL. Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity. J Med Chem 2017;60:3933-57. [PMID: 28406646 DOI: 10.1021/acs.jmedchem.7b00233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
19 Park SW, Kim M, Kim M, D'Agati VD, Lee HT. Sphingosine kinase 1 protects against renal ischemia-reperfusion injury in mice by sphingosine-1-phosphate1 receptor activation. Kidney Int 2011;80:1315-27. [PMID: 21849969 DOI: 10.1038/ki.2011.281] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
20 Tsai H, Han MH. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation. Drugs 2016;76:1067-79. [DOI: 10.1007/s40265-016-0603-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 12.2] [Reference Citation Analysis]
21 Kim M, Park SW, Kim M, D'Agati VD, Lee HT. Isoflurane activates intestinal sphingosine kinase to protect against bilateral nephrectomy-induced liver and intestine dysfunction. Am J Physiol Renal Physiol 2011;300:F167-76. [PMID: 20962114 DOI: 10.1152/ajprenal.00467.2010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
22 Santos WL, Lynch KR. Drugging sphingosine kinases. ACS Chem Biol 2015;10:225-33. [PMID: 25384187 DOI: 10.1021/cb5008426] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
23 Schrecengost RS, Green CL, Zhuang Y, Keller SN, Smith RA, Maines LW, Smith CD. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther 2018;365:107-16. [PMID: 29434052 DOI: 10.1124/jpet.117.245738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Sukocheva OA, Lukina E, McGowan E, Bishayee A. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. Adv Protein Chem Struct Biol 2020;120:123-58. [PMID: 32085881 DOI: 10.1016/bs.apcsb.2019.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Suh JH, Degagné É, Gleghorn EE, Setty M, Rodriguez A, Park KT, Verstraete SG, Heyman MB, Patel AS, Irek M, Gildengorin GL, Hubbard NE, Borowsky AD, Saba JD. Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease: A Matched-case Control Pilot Study. Inflamm Bowel Dis 2018;24:1321-34. [PMID: 29788359 DOI: 10.1093/ibd/izy007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
26 Kabel AM, Omar MS, Balaha MF, Borg HM. Effect of metformin and adriamycin on transplantable tumor model. Tissue Cell 2015;47:498-505. [PMID: 26276089 DOI: 10.1016/j.tice.2015.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ghosh M, Thangada S, Dasgupta O, Khanna KM, Yamase HT, Kashgarian M, Hla T, Shapiro LH, Ferrer FA. Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS One 2018;13:e0194053. [PMID: 29518138 DOI: 10.1371/journal.pone.0194053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lynch KR, Thorpe SB, Santos WL. Sphingosine kinase inhibitors: a review of patent literature (2006-2015). Expert Opin Ther Pat 2016;26:1409-16. [PMID: 27539678 DOI: 10.1080/13543776.2016.1226282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
29 Pyne S, Adams DR, Pyne NJ. Sphingosine Kinases as Druggable Targets. In: Gomez-cambronero J, Frohman MA, editors. Lipid Signaling in Human Diseases. Cham: Springer International Publishing; 2020. pp. 49-76. [DOI: 10.1007/164_2018_96] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
30 Xie Z, Liu H, Geng M. Targeting sphingosine-1-phosphate signaling for cancer therapy. Sci China Life Sci 2017;60:585-600. [DOI: 10.1007/s11427-017-9046-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 Lewis CS, Voelkel-Johnson C, Smith CD. Targeting Sphingosine Kinases for the Treatment of Cancer. Adv Cancer Res 2018;140:295-325. [PMID: 30060814 DOI: 10.1016/bs.acr.2018.04.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
32 Zu Heringdorf DM, Ihlefeld K, Pfeilschifter J. Pharmacology of the sphingosine-1-phosphate signalling system. Handb Exp Pharmacol 2013;:239-53. [PMID: 23579459 DOI: 10.1007/978-3-7091-1368-4_13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
33 Vogt D, Weber J, Ihlefeld K, Brüggerhoff A, Proschak E, Stark H. Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors. Bioorganic & Medicinal Chemistry 2014;22:5354-67. [DOI: 10.1016/j.bmc.2014.07.044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
34 Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Prog Lipid Res 2016;62:93-106. [PMID: 26970273 DOI: 10.1016/j.plipres.2016.03.001] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 19.0] [Reference Citation Analysis]
35 Cahalan SM. Chemical and genetic tools to explore S1P biology. Curr Top Microbiol Immunol 2014;378:55-83. [PMID: 24728593 DOI: 10.1007/978-3-319-05879-5_3] [Reference Citation Analysis]
36 Adada MM, Canals D, Jeong N, Kelkar AD, Hernandez-Corbacho M, Pulkoski-Gross MJ, Donaldson JC, Hannun YA, Obeid LM. Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion. FASEB J 2015;29:4654-69. [PMID: 26209696 DOI: 10.1096/fj.15-274340] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
37 Adams DR, Tawati S, Berretta G, Rivas PL, Baiget J, Jiang Z, Alsfouk A, Mackay SP, Pyne NJ, Pyne S. Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2. J Med Chem 2019;62:3658-76. [DOI: 10.1021/acs.jmedchem.9b00162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
38 Magli E, Corvino A, Fiorino F, Frecentese F, Perissutti E, Saccone I, Santagada V, Caliendo G, Severino B. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments. Curr Pharm Des 2019;25:956-68. [PMID: 30947653 DOI: 10.2174/1381612825666190404115424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Sharma AK. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opinion on Therapeutic Patents 2011;21:807-12. [DOI: 10.1517/13543776.2011.573787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
40 Diaz Escarcega R, McCullough LD, Tsvetkov AS. The Functional Role of Sphingosine Kinase 2. Front Mol Biosci 2021;8:683767. [PMID: 34055895 DOI: 10.3389/fmolb.2021.683767] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Furuya H, Choi S, Obeid LM, Kawamori T, Snider AJ. Colon Cancer: The Role of Sphingolipid Metabolic Enzymes. In: Hannun YA, Luberto C, Mao C, Obeid LM, editors. Bioactive Sphingolipids in Cancer Biology and Therapy. Cham: Springer International Publishing; 2015. pp. 141-59. [DOI: 10.1007/978-3-319-20750-6_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Sun WY, Bonder CS. Sphingolipids: a potential molecular approach to treat allergic inflammation. J Allergy (Cairo) 2012;2012:154174. [PMID: 23316248 DOI: 10.1155/2012/154174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem 2015;58:1879-99. [PMID: 25643074 DOI: 10.1021/jm501760d] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
44 Artru F, McPhail MJW, Triantafyllou E, Trovato FM. Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids. Front Immunol 2022;13:867261. [PMID: 35432367 DOI: 10.3389/fimmu.2022.867261] [Reference Citation Analysis]
45 Castro-gómez P, Garcia-serrano A, Visioli F, Fontecha J. Relevance of dietary glycerophospholipids and sphingolipids to human health. Prostaglandins, Leukotrienes and Essential Fatty Acids 2015;101:41-51. [DOI: 10.1016/j.plefa.2015.07.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 54] [Article Influence: 11.3] [Reference Citation Analysis]
46 Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, Santos WL. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 2012;447:149-57. [PMID: 22747486 DOI: 10.1042/BJ20120609] [Cited by in Crossref: 70] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
47 Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther 2011;132:352-60. [PMID: 21906625 DOI: 10.1016/j.pharmthera.2011.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
48 Vogt D, Stark H. Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. Med Res Rev 2017;37:3-51. [PMID: 27480072 DOI: 10.1002/med.21402] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
49 Snider AJ. Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease. Int J Clin Rheumtol 2013;8. [PMID: 24416079 DOI: 10.2217/ijr.13.40] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
50 Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489-503. [PMID: 20555359 DOI: 10.1038/nrc2875] [Cited by in Crossref: 585] [Cited by in F6Publishing: 571] [Article Influence: 48.8] [Reference Citation Analysis]
51 Pyne NJ, Adams DR, Pyne S. Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. Trends in Pharmacological Sciences 2017;38:581-91. [DOI: 10.1016/j.tips.2017.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
52 Sattar RSA, Sumi MP, Nimisha, Apurva, Kumar A, Sharma AK, Ahmad E, Ali A, Mahajan B, Saluja SS. S1P signaling, its interactions and cross-talks with other partners and therapeutic importance in colorectal cancer. Cell Signal 2021;86:110080. [PMID: 34245863 DOI: 10.1016/j.cellsig.2021.110080] [Reference Citation Analysis]
53 Gangoiti P, Camacho L, Arana L, Ouro A, Granado MH, Brizuela L, Casas J, Fabriás G, Abad JL, Delgado A, Gómez-Muñoz A. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Prog Lipid Res 2010;49:316-34. [PMID: 20193711 DOI: 10.1016/j.plipres.2010.02.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 8.3] [Reference Citation Analysis]
54 Pitman MR, Costabile M, Pitson SM. Recent advances in the development of sphingosine kinase inhibitors. Cellular Signalling 2016;28:1349-63. [DOI: 10.1016/j.cellsig.2016.06.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
55 Sanllehí P, Abad JL, Casas J, Delgado A. Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase). Chem Phys Lipids 2016;197:69-81. [PMID: 26200919 DOI: 10.1016/j.chemphyslip.2015.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
56 Chew WS, Wang W, Herr DR. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. Pharmacological Research 2016;113:521-32. [DOI: 10.1016/j.phrs.2016.09.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
57 Nielsen OH, Li Y, Johansson-lindbom B, Coskun M. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. Trends in Molecular Medicine 2017;23:362-74. [DOI: 10.1016/j.molmed.2017.02.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
58 Vaidya A, Jain S, Sahu S, Jain PK, Pathak K, Pathak D, Kumar R, Jain SK. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway. MRMC 2020;20:886-907. [DOI: 10.2174/1389557520666200212105417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
59 Li H, Sibley CD, Kharel Y, Huang T, Brown AM, Wonilowicz LG, Bevan DR, Lynch KR, Santos WL. Lipophilic tail modifications of 2-(hydroxymethyl)pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors. Bioorg Med Chem 2021;30:115941. [PMID: 33385956 DOI: 10.1016/j.bmc.2020.115941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Fitzpatrick LR. Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Int J Inflam. 2012;2012:389404. [PMID: 22506136 DOI: 10.1155/2012/389404] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]